Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (DE:3G0)
FRANKFURT:3G0
Holding DE:3G0?
Track your performance easily
3G0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.14 - €13.70
Previous Close€9.02
Volume0.00
Average Volume (3M)1.22K
Market Cap
€634.70M
Enterprise Value€503.81M
Total Cash (Recent Filing)$139.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 27, 2025EPS Estimate
-€0.33Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,070,951
10 Day Avg. Volume1,680
30 Day Avg. Volume1,218
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.64
Price to Sales (P/S)1649.05
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.69K
Enterprise Value/Gross Profit1.18K
Enterprise Value/Ebitda-5.02
Forecast
1Y Price Target
€20.70Price Target Upside129.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Altimmune News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressAltimmune completed enrollment in the Phase 2 IMPACT trial in NASH patients.
Market OpportunityThe scarcity of similar candidates in biotech companies positions pemvidutide favorably in the market.
Product DifferentiationPemvidutide is considered one of the most potent in its class, balancing efficacy with superior tolerability.
Bears Say
Core Value DependencyHepTcell Ph. II trial discontinuation making pemvi the core value-driver.
Pipeline SetbacksThe company is discontinuing development of hepatitis B candidate HepTCell which was considered an upside.
Product DevelopmentSurvodutide data show one of the worst tolerability profiles for a GLP-based candidate.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.83% Insiders
11.78% Mutual Funds
2.12% Other Institutional Investors
71.05% Public Companies and
Individual Investors
3G0 FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was €2.14 and its highest was €13.70 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Mar 27, 2025 which is in 133 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Nov 12, 2024. The company reported -€0.303 earnings per share for the quarter, beating the consensus estimate of -€0.338 by €0.035.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of €819.83 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -€0.33.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 71,070,950 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -€0.303 in its last earnings report, beating expectations of -€0.338. Following the earnings report the stock price went up 24.779%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Ardsley Advisory Partners. It holds Altimmune Inc’s shares valued at 2M.
---
Altimmune Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€20.70 (129.55% Upside)
€20.70 (129.55% Upside)
Blogger Sentiment
Bullish
DE:3G0 Sentiment 97%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $110.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
290.16%
12-Months-Change
Fundamentals
Return on Equity
-72.96%
Trailing 12-Months
Asset Growth
-11.23%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
3G0 Earnings Call
Q3 2024
0:00 / 0:00
---
3G0 Stock 12 Month Forecast
Average Price Target
€20.70
▲(129.55% Upside)
Technical Analysis
Best Analysts Covering 3G0
1 Year
1 Year Success Rate
19/35 ratings generated profit
1 Year Average Return
+15.17%
reiterated a buy rating yesterday
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 54.29% of your transactions generating a profit, with an average return of +15.17% per trade.
---